参芪扶正注射液联合化学疗法治疗晚期胃癌25例

目的 评价参芪扶正注射液联合化学疗法治疗晚期胃癌的临床疗效。方法 将50例晚期胃癌患者按照随机数字表法分为观察组和对照组，每组25例。对照组予以化学治疗，观察组在对照组治疗方案基础上加用参芪扶正注射液进行联合治疗。比较两组患者临床疗效，治疗前后血清糖类抗原125（carbohydrate antigen 125, CA125）、癌胚抗原（carcinoma embryo antigen, CEA）水平，中医证候积分，卡氏功能状态（Karnofsky performance status, KPS）评分，癌因性疲乏(cancer related fatigue, CRF)评分，生活质量核心量表- 30（quality of life questionnare- core 30, QLQ- C30）评分以及不良反应发生情况。结果 两组患者近期肿瘤疗效比较，差异无统计学意义（P>0.05）。与治疗前比较，两组患者治疗后血清CA125、CEA水平明显下降（P＜0.05），且观察组患者治疗后血清CA125、CEA水平降低程度显著大于对照组（P＜0.05）。与治疗前比较，两组患者治疗后中医证候积分显著下降（P＜0.05），KPS评分显著升高（P＜0.05）；与对照组比较，观察组中医证候积分、KPS评分改善更显著（P＜0.05）。与治疗前比较，观察组患者治疗后CRF总分及行为、躯体、认知评分均显著降低（P＜0.05），而对照组患者治疗后躯体评分显著增加（P＜0.05）。两组基于QLQ- C30评分的疗效比较，差异有统计学意义（P<0.05），观察组疗效显著优于对照组。与对照组比较，观察组患者血小板减少、血红蛋白下降、白细胞减少、恶心呕吐、乏力的不良反应发生率均显著降低，差异有统计学意义（P<0.05）。结论 参芪扶正注射液联合化学治疗能够显著提高晚期胃癌患者的疗效，降低化学治疗药物的不良反应，改善患者生存质量。

Clinical Effect of Shenqi Fuzheng Injection Combined with Chemotherapy in Treatment of Advanced Gastric Cancer: An Analysis of 25 Cases

Objective To investigate the clinical effect of Shenqi Fuzheng Injection combined with chemotherapy in the treatment of advanced gastric cancer. Methods A total of 50 patients with advanced gastric cancer were divided into observation group and control group using a random number table, with 25 patients in each group.The patients in the control group were given chemotherapy, and those in the observation group were given Shenqi Fuzheng Injection combined with the treatment regimen in the control group.The two groups were compared in terms of clinical outcome, serum levels of carbohydrate antigen 125 (CA125) and carcinoembryonic antigen (CEA) before and after treatment, traditional Chinese medicine (TCM) syndrome score, Karnofsky Performance Scale (KPS) score, cancer- related fatigue (CRF) score, quality of life questionnaire- core 30 (QLQ- C30) score, and adverse reactions.Results There was no significant difference in the short- term outcome of tumor between the two groups (P>0.05). After treatment, both groups had significant reductions in the serum levels of CA125 and CEA (P<0.05), and the observation group had significantly greater reductions than the control group (P<0.05). After treatment, both groups had a significant reduction in TCM syndrome score (P<0.05) and a significant increase in KPS score (P<0.05), and the observation group had significantly greater improvements in TCM syndrome score and KPS score than the control group (P<0.05). After treatment, the observation group had significant reductions in total CRF score and behavioral, somatic, and cognitive scores(P<0.05), while the control group had a significant increase in somatic score (P<0.05). There was a significant difference in treatment outcome based on QLQ- C30 score between the two groups (P<0.05), and the observation group had a significantly better treatment outcome than the control group. Compared with the control group, the observation group had significantly lower incidence rates of adverse reactions such as thrombocytopenia, reduction in hemoglobin, leucopenia, nausea and vomiting, and weakness(P<0.05). Conclusion In the treatment of patients with advanced gastric cancer, Shenqi Fuzheng Injection combined with chemotherapy can significantly improve treatment outcome, reduce the adverse reactions of chemotherapy drugs, and improve quality of life.